Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2017-01-04 | Forward | 2:1 |
| 2015-07-01 | Forward | 553:500 |
| 1998-05-26 | Reverse | 1:2 |
Integra LifeSciences develops and markets surgical implants, instruments, and regenerative products for neurosurgery, reconstruction, and general surgery worldwide through direct sales and distribution channels.
Integra's advanced ultrasonic surgical system, FDA-cleared in November 2025 for cardiac surgeries, enables precise tissue fragmentation, emulsification, and aspiration, showcasing its innovative focus in complex surgical procedures.
Integra LifeSciences announced a GAAP net loss of $(484.1) million, or $(6.31) per diluted share, for the second quarter of 2025. This was a dramatic increase from the $(12.4) million net loss in the same period of the prior year and was primarily driven by a significant $511 million goodwill impairment charge. The company attributed the charge to a decrease in its stock price related to factors including recent tariff changes, as well as quality, operational, and supply issues.
Following the appointment of new President and CEO Mojdeh Poul in January 2025, Integra LifeSciences launched a comprehensive "Compliance Master Plan" to address significant operational deficiencies, including FDA warning letters. [1, 11, 16] This strategic overhaul involves extensive remediation at its manufacturing sites and the establishment of a new Transformation and Program Management Office to improve execution and resolve systemic supply chain issues that have led to major product shipping holds. [11, 13]
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Integra (IART) To Contact Him Directly To Discuss Their Options
PRINCETON, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2026 financial results on Wednesday, October 21, 2026, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET.
NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired Integra securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to learn more about your rights.
Nasdaq Hits Fresh Highs While Dow Slips and Small Caps Struggle for DirectionPR NewswireNEW YORK, Oct. 5, 2026NEW YORK, Oct. 5, 2026 /PRNewswire/ -- Stock Preac
SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, is investigating Integra LifeSciences Holdings Corporation (NASDAQ: IART) on behalf of investors who may have suffered losses. If you purchased Integra securities and suffered losses, please contact the firm to learn more about the investigation. There is no cost or obligation.
San Diego, California--(Newsfile Corp. - October 4, 2026) - Johnson Fistel, PLLP, a leading stockholder rights law firm, is investigating Integra LifeSciences Holdings Corporation (NASDAQ: IART) on behalf of investors who may have suffered losses. If you purchased Integra securities and suffered losses, please contact the firm to learn more about the investigation.
Integra LifeSciences (NASDAQ: IART - Get Free Report) issued an update on its FY 2026 earnings guidance on Friday. The company provided EPS guidance of 2.300-2.400 for the period, compared to the consensus EPS estimate of 2.460. The company issued revenue guidance of $1.6 billion-$1.7 billion. Integra LifeSciences also updated its Q3 2026 guidance to 0.550-0.590
/PRNewswire/ -- Stock Preachers News Commentary - Big technology names pulled the Nasdaq Composite to a weekly gain while the Dow Jones Industrial Average and
A $4.3 million to $6.3 million gap between Integra's preliminary third-quarter revenue and the Wall Street estimate sent IART shares lower. SueWallSt notifies investors of a pending investigation into potential securities claims for shareholders who lost money.
Integra Lifesciences Holdings Corp (NASDAQ:IART) cut its 2026 revenue and adjusted earnings guidance after July flooding disrupted operations in Cincinnati, despite expectations for strong cash generation. The medical technology company now forecasts annual revenue of $1.634 billion to $1.654 billion, down from $1.654 billion to $1.695 billion.
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
 SYK | $274.98 | COMPARE |
 SNN | $26.93 | COMPARE |
 GMED | $73.53 | COMPARE |
 BFLY | $8.74 | COMPARE |
 FTRE | $21.55 | COMPARE |
 AXGN | $35.92 | COMPARE |
 SEPN | $35.91 | COMPARE |
 ATEC | $10.24 | COMPARE |
